Author:
Khoury H.J.,Gambacorti-Passerini C.,Brümmendorf T.H.
Reference35 articles.
1. BosulifTM (bosutinib). Summary of Product Characteristics. Pfizer Inc, Sandwich, Kent, UK, 2013.
2. Bosulif® (bosutinib). Full Prescribing Information, Pfizer Labs, Pfizer Inc, New York, NY, USA, 2017.
3. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib;Cortes;Blood,2011
4. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up;Gambacorti-Passerini;Am J Hematol,2014
5. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib;Brummendorf;Br J Haematol,2016
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献